- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01014117
Effect of SRT2104 on Endotoxin-induced Inflammation
A Phase I Study to Evaluate Single and Multiple (Seven) Oral Doses of SRT2104 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
Amsterdam, Nederland, 1105 AZ
- GSK Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Healthy, as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination and laboratory tests carried out within 28 days prior to day 1. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
- Male between 18 and 35 years of age inclusive, at the time of signing the informed consent
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
- No history of HIV 1 and 2, and hepatitis B and C
- Normal 12 lead ECG without any clinically significant abnormality as judged by the Investigator and average QTcB or QTcF < 450 msec
- Normal renal and liver function (normal serum creatinine and liver function tests (ALT, AST, Total bilirubin, alkaline phosphatase)
- Subjects must agree with their partners to use double-barrier birth control or abstinence while participating in the study and for 12 weeks following the last dose of study drug
Exclusion Criteria:
- As a result of the medical interview, physical examination or screening investigations, the Investigator or appropriately qualified designee considers the subject unfit for the study
- Subject has had a major illness in the past three months or any significant chronic medial illness that the investigator would deem unfavourable for enrolment including inflammatory diseases
- Subjects with a history of any type of malignancy with the exception of successfully treated basal cell cancer of the skin
- Subject has renal impairment
- Subject has a past or current gastro-intestinal disease which may influence drug absorption
- The subject has a known positive test for hepatitis C antibody or hepatitis B surface antigen
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- The subject has a known positive test for HIV antibody 1 or 2
- Subject has a history, within three years, of drug abuse (including benzodiazepines, opioids, amphetamine, cocaine, THC) or a positive drug results at the Screening visit
- History of alcoholism and/or is drinking more than 3 drinks per day. Alcoholism is defined as an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
- The subject has participated in a clinical trial and has received an investigational product within three months of the first dosing day in the current study
- Use of prescription or non-prescription drugs, and herbal and dietary supplements within 7 days unless in the opinion of the Investigator and Medical Monitor the medication will not interfere with the study procedures or compromise subject safety
- Subject has difficultly in donating blood or accessibility of a vein in left or right arm
- Subject has donated more than 350 mL of blood in last 3 months
- Subject uses tobacco products
- Any other issue that, in the opinion of the Principal Investigator, would could be harmful to the subject or compromise interpretation of the data
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Placebo-vergelijker: Placebo
The Placebo treatment group will be administered eight oral placebo capsules once daily for 7 days. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days. |
Bijpassende placebo wordt geleverd in de vorm van harde gelatinecapsules, die elk een geschikte hoeveelheid placebo bevatten.
|
Actieve vergelijker: Placebo and 2.0g SRT2104
This treatment group will be administered eight oral placebo capsules once daily for 6 days followed by 2.0g SRT2104 administered as eight oral SRT2104 capsules on Day 7. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center.
During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home.
Test material should be administered with approximately 400mL of water.
On Days 1 and 7, dosing will occur at approximately 7AM.
Dosing on Days 2-6 will occur before 9AM.
Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
|
Bijpassende placebo wordt geleverd in de vorm van harde gelatinecapsules, die elk een geschikte hoeveelheid placebo bevatten.
SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
|
Actieve vergelijker: 2.0g SRT2104
The 2.0g SRT2104 treatment group will be administered eight oral SRT2104 capsules once daily for 7 days.
A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center.
During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home.
Test material should be administered with approximately 400mL of water.
On Days 1 and 7, dosing will occur at approximately 7AM.
Dosing on Days 2-6 will occur before 9AM.
Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
|
SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
To determine if a single or 7 daily doses of SRT2104 attenuates the inflammatory response in normal healthy male subjects after exposure to low-dose endotoxin (LPS).
Tijdsspanne: Measurements of inflammation will be conducted on plasma samples obtained on Day7 at -3, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12hrs. Samples will also be taken on Day8, approximately 24hrs after dosing on Day7.
|
Measurements of inflammation will be conducted on plasma samples obtained on Day7 at -3, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12hrs. Samples will also be taken on Day8, approximately 24hrs after dosing on Day7.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
To determine PK of SRT2104 in normal healthy male subjects exposed to low-dose endotoxin (LPS).
Tijdsspanne: Plasma samples will be collected at pre-dose, 15min, 30min, and 1, 2, 3, 4, 8, and 12hrs post-dose on Day1 and Day7. Plasma samples will also be collected on Day2 and Day8 and at 24hrs post-dose Day1 and Day7, respectively.
|
Plasma samples will be collected at pre-dose, 15min, 30min, and 1, 2, 3, 4, 8, and 12hrs post-dose on Day1 and Day7. Plasma samples will also be collected on Day2 and Day8 and at 24hrs post-dose Day1 and Day7, respectively.
|
To determine the safety profile of SRT2104 in healthy male subjects exposed to low-dose endotoxin (LPS).
Tijdsspanne: Safety will be monitored by AEs, VS, physical exam, labs and ECGs during the course of the study.
|
Safety will be monitored by AEs, VS, physical exam, labs and ECGs during the course of the study.
|
To determine the effect of SRT2104 on other parameters following low-dose endotoxin (LPS) exposure in humans e.g., lipid profile, serum amyloid phospholipids, metabolic profiles and gene expression analysis etc.
Tijdsspanne: Blood samples will be collected for exploratory gene expression analysis pre-dose on Days1 and 7, and 4hrs after LPS exposure on Day7. Samples for other parameters will be collected during fasting, pre-dose on Days1 and 7 and 24hrs post-dose on Day8.
|
Blood samples will be collected for exploratory gene expression analysis pre-dose on Days1 and 7, and 4hrs after LPS exposure on Day7. Samples for other parameters will be collected during fasting, pre-dose on Days1 and 7 and 24hrs post-dose on Day8.
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- van der meer, AJ, Scicluno, B, Lin, J, Jacobson, EW, Vlasuk, GP, van der Poll. The first demonstration of clinical activity by a small molcule SIRT1 activator: SRT 2104 reduces cytokine release and coagulation activation in a human enotoxin model. [Inflammation Research]. 2011;60(Supplement 1):S1-321.
- van der Meer AJ, Scicluna BP, Moerland PD, Lin J, Jacobson EW, Vlasuk GP, van der Poll T. The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans. Crit Care Med. 2015 Jun;43(6):e199-202. doi: 10.1097/CCM.0000000000000949.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- 114009
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Bestudeer gegevens/documenten
-
Specificatie gegevensset
Informatie-ID: 114009Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Gegevensset individuele deelnemers
Informatie-ID: 114009Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistisch analyseplan
Informatie-ID: 114009Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Leerprotocool
Informatie-ID: 114009Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisch onderzoeksrapport
Informatie-ID: 114009Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulier geïnformeerde toestemming
Informatie-ID: 114009Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Sepsis
-
University of Kansas Medical CenterUniversity of KansasWervingSepsis | Septische shock | Sepsis-syndroom | Sepsis, ernstig | Sepsis Bacterieel | Sepsis-bacteriëmieVerenigde Staten
-
Jip GroenInBiomeWervingMicrobiële kolonisatie | Neonatale infectie | Neonatale sepsis, vroege aanvang | Microbiële ziekte | Klinische sepsis | Kweeknegatieve neonatale sepsis | Neonatale sepsis, late aanvang | Kweek positieve neonatale sepsisNederland
-
The University of QueenslandRoyal Brisbane and Women's HospitalOnbekend
-
Karolinska InstitutetÖrebro University, SwedenVoltooidSepsis | Sepsis-syndroom | Sepsis, ernstigZweden
-
Ohio State UniversityVoltooidSepsis, ernstige sepsis en septische shockVerenigde Staten
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsVoltooidSepsis | Septische shock | Ernstige sepsis | Sepsis-syndroomVerenigd Koninkrijk
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityWervingErnstige sepsis | Ernstige sepsis zonder septische shockVerenigde Staten
-
Indonesia UniversityVoltooidErnstige sepsis met septische shock | Ernstige sepsis zonder septische shockIndonesië
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital en andere medewerkersVoltooidSepsis | Septische shock | Ernstige sepsis | Infectie | Sepsis-syndroomVerenigde Staten
-
Inverness Medical InnovationsVoltooidSepsis | Systemisch ontstekingsreactiesyndroom | Ernstige sepsis | Sepsis-syndroomVerenigde Staten
Klinische onderzoeken op Placebo
-
SamA Pharmaceutical Co., LtdOnbekendAcute bronchitis | Acute bovenste luchtweginfectieKorea, republiek van
-
National Institute on Drug Abuse (NIDA)VoltooidCannabisgebruikVerenigde Staten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyVoltooidMannelijke proefpersonen met diabetes type II (T2DM)Duitsland
-
Heptares Therapeutics LimitedVoltooidFarmacokinetiek | Veiligheid problemenVerenigd Koninkrijk
-
Texas A&M UniversityNutraboltVoltooidGlucose and Insulin Response
-
Soroka University Medical CenterVoltooid
-
Regado Biosciences, Inc.VoltooidGezonde vrijwilligerVerenigde Staten
-
Longeveron Inc.BeëindigdHypoplastisch linkerhartsyndroomVerenigde Staten
-
ItalfarmacoVoltooidBecker spierdystrofieNederland, Italië